NewAmsterdam Pharma (NASDAQ:NAMS) Issues Quarterly Earnings Results, Misses Estimates By $0.47 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) announced its quarterly earnings results on Wednesday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47), Zacks reports.

NewAmsterdam Pharma Trading Up 8.3 %

Shares of NAMS traded up $1.48 during mid-day trading on Wednesday, reaching $19.36. 578,964 shares of the company’s stock were exchanged, compared to its average volume of 635,529. The company has a 50-day simple moving average of $22.86 and a two-hundred day simple moving average of $20.25. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the completion of the transaction, the insider now directly owns 11,150,461 shares of the company’s stock, valued at $283,110,204.79. This trade represents a 1.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 404,927 shares of company stock worth $10,390,787 in the last quarter. 19.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on NAMS. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $41.60.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.